HRP20171180T4 - Pegilirana l-asparaginaza - Google Patents
Pegilirana l-asparaginaza Download PDFInfo
- Publication number
- HRP20171180T4 HRP20171180T4 HRP20171180TT HRP20171180T HRP20171180T4 HR P20171180 T4 HRP20171180 T4 HR P20171180T4 HR P20171180T T HRP20171180T T HR P20171180TT HR P20171180 T HRP20171180 T HR P20171180T HR P20171180 T4 HRP20171180 T4 HR P20171180T4
- Authority
- HR
- Croatia
- Prior art keywords
- conjugate
- use according
- peg
- asparaginase
- seq
- Prior art date
Links
- 108010001564 pegaspargase Proteins 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 13
- 239000002202 Polyethylene glycol Substances 0.000 claims 12
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims 10
- 108010024976 Asparaginase Proteins 0.000 claims 10
- 125000003277 amino group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 241000588700 Dickeya chrysanthemi Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Konjugat za upotrebu u terapiji, pri čemu konjugat sadrži L-asparaginazu iz Erwinia chrysanthemi koja je bar 90% identična aminokiselinskoj sekvenci SEQ ID NO: 1 i polietilen glikol (PEG), gdje PEG ima molekulsku masu manju ili jednaku oko 5000 Da.
2. Konjugat za upotrebu prema zahtjevu 1, gdje spomenuta L-asparaginaza je bar 95% identična aminokiselinskoj sekvenci SEQ ID NO:1, ili je bar 99% identična aminokiselinskoj sekvenci SEQ ID NO:1
3. Konjugat za upotrebu prema zahtjevu 1, gdje je spomenuta L-asparaginaza identična SEQ ID NO:1.
4. Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 3, gdje spomenuti PEG ima molekulsku masu u okviru opsega od bar 500 Da.
5. Konjugat za upotrebu prema zahtjevu 3, gdje spomenuti PEG ima molekulsku masu od oko 5000 Da, manju od oko 5000 Da, manju od oko 4000 Da, manju od oko 3000 Da, ili manju od oko 2500 Da.
6. Konjugat za upotrebu prema zahtjevu 1, gdje je spomenuta L-asparaginaza identična sa SEQ ID NO:1 i spomenuti PEG ima molekulsku masu od oko 5000 Da.
7. Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 6 gdje je PEG kovalentno vezan za jednu ili više amino grupa spomenute L-asparaginaze.
8. Konjugat za upotrebu prema zahtjevu 7, gdje je PEG kovalentno vezan za jednu ili više amino grupa amidnom vezom.
9. Konjugat za upotrebu prema zahtjevu 7 ili 8, gdje je PEG kovalentno vezan sa od 40% do 100% dostupnih amino grupa, naročito između 40% do oko 90% ukupnih amino grupa.
10. Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 9 koji ima formulu:
Asp-[NH-CO(CH2)x-CO-NH-PEG]n
gdje Asp je L-asparaginaza, NH je jedna ili više NH grupa lizinskih ostataka i/ili N-kraj u Asp, PEG je polietilen glikolni dio, n je broj koji predstavlja bar 40% do oko 100% dostupnih amino grupa (npr. ostataka lizina i/ili N-kraja) u Asp, i x je cijeli broj od oko 1 do 8, posebno X je cijeli broj u opsegu od oko 2 do 5.
11. Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 10, gdje je spomenuti PEG monometoksi-polietilen glikol.
12. Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 10 za liječenje pacijenta od bolesti koji se liječe trošenjem L-asparaginaze, opcionalno gdje je spomenuta bolest hematološki malignitet i pacijentu se daje doza od 10 000 internecionalnih jedinica po kvadratnom metru površine tijela pacijenta (IU/m2) do 15 000 IU/m2.
13. Konjugat za upotrebu prema bilo kojem od zahtjeva 1 do 10 za liječenje pacijenta od bolesti koje se liječe trošenjem L-asparaginaze, opcionalno gdje je spomenuta bolest koja se liječi trošenjem asparaginaze tumor, opcionalno gdje je spomenuti tumor izabran iz grupe koju čine akutna limfoblastna leukemija (ALL), nekotchkinov limfom, NK limfom i tumor gušterače.
14. Konjugat za upotrebu prema zahtjevu 13, gdje je spomenuti tumor NK limfom.
15. Konjugat za upotrebu prema zahtjevu 13, gdje je spomenuti pacijent imao recidiv bolesti, opcionalno gdje se spomenuti recidiv bolesti javlja poslije liječenja sa L-asparaginazom E.coli ili njenim PEG-ilovanim oblikom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22332009P | 2009-07-06 | 2009-07-06 | |
| PCT/EP2010/054156 WO2011003633A1 (en) | 2009-07-06 | 2010-03-30 | Pegylated l-asparaginase |
| PCT/EP2010/059599 WO2011003886A1 (en) | 2009-07-06 | 2010-07-06 | Pegylated l-asparaginase |
| EP10730170.7A EP2451486B2 (en) | 2009-07-06 | 2010-07-06 | Pegylated l-asparaginase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20171180T1 HRP20171180T1 (hr) | 2018-01-26 |
| HRP20171180T4 true HRP20171180T4 (hr) | 2023-06-09 |
Family
ID=42670528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171180TT HRP20171180T4 (hr) | 2009-07-06 | 2010-07-06 | Pegilirana l-asparaginaza |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2451486B2 (hr) |
| CY (1) | CY1119779T1 (hr) |
| HR (1) | HRP20171180T4 (hr) |
| ME (1) | ME02945B (hr) |
| PL (1) | PL2451486T5 (hr) |
| RS (1) | RS57077B2 (hr) |
| SI (1) | SI2451486T2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| EP3700921A4 (en) * | 2017-10-27 | 2021-12-15 | Pfenex Inc. | PROCESS FOR THE PRODUCTION OF RECOMBINANT ERWINIA ASPARAGINASE |
| CN110684759B (zh) * | 2018-07-06 | 2023-10-17 | 南京吉芮康生物科技研究院有限公司 | 重组l-门冬酰胺酶及其制备方法和用途 |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
-
2010
- 2010-07-06 PL PL10730170.7T patent/PL2451486T5/pl unknown
- 2010-07-06 EP EP10730170.7A patent/EP2451486B2/en active Active
- 2010-07-06 SI SI201031521T patent/SI2451486T2/sl unknown
- 2010-07-06 RS RS20170778A patent/RS57077B2/sr unknown
- 2010-07-06 ME MEP-2017-171A patent/ME02945B/me unknown
- 2010-07-06 HR HRP20171180TT patent/HRP20171180T4/hr unknown
-
2017
- 2017-08-03 CY CY20171100834T patent/CY1119779T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2451486T2 (sl) | 2023-05-31 |
| ME02945B (me) | 2018-04-20 |
| CY1119779T1 (el) | 2018-06-27 |
| RS57077B1 (sr) | 2018-06-29 |
| RS57077B2 (sr) | 2023-06-30 |
| SI2451486T1 (en) | 2018-01-31 |
| HRP20171180T1 (hr) | 2018-01-26 |
| EP2451486B2 (en) | 2023-01-18 |
| PL2451486T3 (pl) | 2018-02-28 |
| PL2451486T5 (pl) | 2023-05-15 |
| EP2451486B1 (en) | 2017-05-03 |
| EP2451486A1 (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171180T4 (hr) | Pegilirana l-asparaginaza | |
| FI2451486T4 (fi) | Pegyloitu L-asparaginaasi | |
| JP2012532185A5 (hr) | ||
| HRP20191852T1 (hr) | Polipeptidi | |
| KR100806088B1 (ko) | 히알루론산과 폴리에틸렌이민으로 이루어진 양이온성고분자 접합체를 이용한 핵산 전달용 조성물 | |
| AU2005314468B2 (en) | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases | |
| Etrych et al. | Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours | |
| JP2019517553A5 (hr) | ||
| AU2009302387B2 (en) | HPMA - docetaxel or gemcitabine conjugates and uses therefore | |
| JP2008542399A5 (hr) | ||
| ES2743509T3 (es) | Métodos, usos y composiciones de agonistas de Tie2 | |
| WO2008076333A8 (en) | Polymer-drug conjugates with tether groups for controlled drug delivery | |
| HRP20210184T1 (hr) | Peptidni dendrimeri koji sadrže fibrinogen-vezujuće peptide | |
| HRP20210877T1 (hr) | Antisens polinukleotidi za induciranje preskakanja egzona i postupci liječenja distrofija | |
| JP2010532168A5 (hr) | ||
| EP2147122B1 (en) | Enzymatic anticancer therapy | |
| BR0306993A (pt) | Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c | |
| WO2008109432A3 (en) | Therapeutic targeting of interleukins using sirna in neutral liposomes | |
| CN106687121A (zh) | 改善的聚乙烯亚胺聚乙二醇载体 | |
| JP2017523781A5 (hr) | ||
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| CA2723823A1 (en) | Conjugates for the treatment of mesothelioma | |
| JP2009540842A5 (hr) | ||
| JP7133225B2 (ja) | 治療用多標的コンストラクトおよびその使用 | |
| HRP20210139T1 (hr) | Sastavi i postupci za korigiranje mišične distrofije donjih udova tipa 2c upotrebom preskakanja egzona |